Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules.

ABSTRACT: This review, one in a series on myotonic dystrophy (DM), is focused on the development and potential use of small molecules as therapeutics for DM. The complex mechanisms and pathogenesis of DM are covered in the associated reviews. Here, we examine the various small molecule approaches taken to target the DNA, RNA, and proteins that contribute to disease onset and progression in myotonic dystrophy type 1 (DM1) and 2 (DM2).

SUBMITTER: Reddy K 

PROVIDER: S-EPMC6720693 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature